{"id":"daily-infusion-of-dornase-alfa","safety":{"commonSideEffects":[{"rate":null,"effect":"Voice hoarseness"},{"rate":null,"effect":"Pharyngitis"},{"rate":null,"effect":"Laryngitis"},{"rate":null,"effect":"Chest pain"},{"rate":null,"effect":"Hemoptysis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Dornase alfa cleaves extracellular deoxyribonucleic acid (DNA) that accumulates in respiratory secretions, particularly in cystic fibrosis patients where neutrophil-derived DNA contributes to thick, sticky mucus. By degrading this DNA, the enzyme reduces sputum viscosity and elasticity, facilitating mucociliary clearance and improving airway function. This mechanism helps reduce airway obstruction and infection risk in patients with compromised lung function.","oneSentence":"Dornase alfa is a recombinant human DNase that breaks down extracellular DNA in mucus to reduce viscosity and improve clearance.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:31:07.845Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis (investigational use in Phase 2 by Fondation Ophtalmologique Adolphe de Rothschild, likely for ocular or systemic manifestations)"}]},"trialDetails":[{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT06723717","phase":"PHASE2","title":"Efficacy of Daily IV Administration of Dornase Alfa Up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence At 6 Months","status":"NOT_YET_RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2025-04","conditions":"Ruptured Aneurysm of Intracranial Artery, SAH (Subarachnoid Hemorrhage), Delayed Cerebral Ischemia","enrollment":304},{"nctId":"NCT01478698","phase":"PHASE1","title":"The Safety and Tolerability of Intra-abdominal t-PA and DNase on Peritonitis in Peritoneal Dialysis Patients","status":"TERMINATED","sponsor":"Sir Charles Gairdner Hospital","startDate":"2016-01-01","conditions":"Peritoneal Dialysis, Peritoneal Dialysis, Continuous Ambulatory","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Daily infusion of dornase alfa","genericName":"Daily infusion of dornase alfa","companyName":"Fondation Ophtalmologique Adolphe de Rothschild","companyId":"fondation-ophtalmologique-adolphe-de-rothschild","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dornase alfa is a recombinant human DNase that breaks down extracellular DNA in mucus to reduce viscosity and improve clearance. Used for Cystic fibrosis (investigational use in Phase 2 by Fondation Ophtalmologique Adolphe de Rothschild, likely for ocular or systemic manifestations).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}